ANN ARBOR, Mich., Jan. 15 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Stephen Gracon, D.V.M., as Vice President of Regulatory Affairs.
In his new role, Dr. Gracon will lead the regulatory and quality assurance activities for the company’s rich pipeline of anti-infective products and mucosal vaccines.
Dr. Gracon brings 30 years of experience to NanoBio in diverse areas within the pharmaceutical industry, including pathology and experimental toxicology, clinical research, and regulatory affairs within the United States and internationally. Dr. Gracon served in various clinical, research and regulatory positions at Parke-Davis, Pfizer, Amgen and Baxter prior to joining NanoBio. He has a unique combination of experience with both small and large molecules in a broad range of indications, as well as with seasonal and pandemic vaccines and plasma-derived products.
“NanoBio’s platform is very unique and has tremendous potential far beyond the current indications under investigation,” said Dr. Gracon. “My role is to develop and execute strategies with the NanoBio team to navigate and expedite the FDA approval process for the numerous topical agents and vaccines that can be developed from our proprietary nanotechnology platform.”
“We are very fortunate to have Dr. Gracon’s extensive regulatory experience as we prepare for multiple regulatory submissions,” added James Baker Jr., M.D., founder and CSO of NanoBio Corporation. “His specialized knowledge of regulatory protocol for both therapeutics and vaccines will be critical to moving NanoBio’s products to FDA approval.”
About NanoBio
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company’s headquarters and laboratory facilities are located in Ann Arbor, Mich.
CONTACT: John Coffey, Vice President of Business Development of NanoBio
Corporation, +1-734-302-9107, john.coffey@nanobio.com
